2025-2034 Growth Prospects of the Tremfya Market: Key Trends and Opportunities Analyzed
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Significant is the Anticipated Growth Rate of the Tremfya Market from 2025 to 2034?
In recent times, the market size for Tremfya has gone up by XX (HCAGR). From 2024 onwards, it’s projected to expand from a value of $XX million to $XX million in 2025, registering a compound annual growth rate (CAGR) of XX%. The outstanding growth experienced in the historic phase can be traced back to factors such as a surge in psoriasis and psoriatic arthritis cases, a heightened emphasis on targeted therapies, increased healthcare funding, the establishment of more specialty clinics, as well as a broader acceptance of biologics in both dermatology and rheumatology.
Over the upcoming years, the market size for Tremfya is projected to experience an XX% FCAGR. By 2029, it is predicted to expand to $XX million, showcasing a Compound Annual Growth Rate (CAGR) of XX%. The expansion in the projected period can be credited to factors such as improved healthcare infrastructure, the rising practice of point-of-care testing, increased funding in healthcare research, and a heightened focus on precision medicine. The forecast period is expected to see major trends like progress in treatment options, personalized medicine methods, technological advances in patient monitoring, the inclusion of Artificial Intelligence (AI), and advancements in injection devices.
Which Macro and Microeconomic Factors Are Accelerating the Growth of the Tremfya Market?
A surge in the incidence of autoimmune diseases is likely to contribute to the expansion of the tremfya market. Autoimmune diseases are characterized by the body’s immune system erroneously assaulting its tissues, cells, or organs, interpreting them as foreign entities. This rising occurrence of autoimmune diseases can be attributed to factors such as genetically-inherited traits, environmental initiators, lifestyle modifications, heightened awareness, and advanced diagnostic techniques. Tremfya, an interleukin-23 (IL-23) targeting monoclonal antibody, eases the management of autoimmune diseases by tempering the excessively reactive immune response, lessening inflammation, and mitigating symptoms in ailments like psoriasis and psoriatic arthritis. For instance, a report by the Australian Institute of Health and Welfare, a government organization based in Australia, revealed in June 2024 that there were 10,000 hospitalizations in Australia due to rheumatoid arthritis in 2022, reflecting a 25% increase from 8,000 the prior year, and a hospitalization rate of 39 per 100,000 individuals. Consequently, the escalating incidence of autoimmune diseases is fuelling the growth of the tremfya market.
Request Your Free Tremfya Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=20343&type=smp
Who Are the Dominant Players Pushing the Boundaries of the Tremfya Market?
Major companies operating in the tremfya market are Johnson & Johnson
How Are Market Trends Revolutionizing the Tremfya Industry in Recent Times?
A significant development in the Tremfya market is obtaining official approvals to increase its therapeutic indications like for moderate-to-severe Crohn’s disease. This step enhances its potential patient pool and market scope. Regulatory approvals are endorsements given by organizations like the FDA or EMA, permitting the marketing of a drug for particular uses post-proving its safety, effectiveness, and quality. As an illustration, in September 2024, Johnson & Johnson, a pharmaceutical company based in the US, got FDA’s nod for Tremfya (guselkumab) to treat adults with moderately to severely active ulcerative colitis, making it the first-ever dual-acting interleukin-23 inhibitor approved for such a condition. This approval owes its credit to the positive findings from the Phase 2b/3 QUASAR study, which revealed that almost half of the patients accomplished clinical remission post 44 weeks of therapy. Tremfya takes aim at interleukin-23, which aids in normalizing the inflammation response in the colon.
Pre-order Your Report for Quick and Easy Delivery!
https://www.thebusinessresearchcompany.com/report/tremfya-global-market-report
How Are the Key Segments of the Tremfya Market Driving Opportunities and Innovations?
The tremfya market covered in this report is segmented –
1) By Indication: Moderate-To-Severe Plaque Psoriasis; Active PsA
2) By Formulation: Subcutaneous Injection; Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies
4) By End User: Adult Patients; Geriatric Patients
Which Geographic Areas Are Influencing the Growth of the Tremfya Market?
North America was the largest region in the tremfy market in 2024. The regions covered in the tremfya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Core Features That Define the Tremfya Market?
Tremfya (guselkumab) is a biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease. It works by inhibiting interleukin-23 (IL-23), a protein involved in the inflammatory processes of these conditions. Tremfya is administered via subcutaneous injection once every 8 weeks after initial loading doses.
Browse Through More Similar Reports By The Business Research Company:
Inflammatory Bowel Disease Treatment Global Market Report 2025
Non-Steroidal Anti-inflammatory Drugs Global Market Report 2025
Anti-Inflammatory Therapeutics Global Market Report 2025
https://thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
